Non-Invasive Cancer Diagnostics

Global Non-Invasive Cancer Diagnostics Market to Reach US$224.3 Billion by 2030

The global market for Non-Invasive Cancer Diagnostics estimated at US$156.4 Billion in the year 2024, is expected to reach US$224.3 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Immunochemistry, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$100.5 Billion by the end of the analysis period. Growth in the Clinical Microbiology segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$42.6 Billion While China is Forecast to Grow at 10.1% CAGR

The Non-Invasive Cancer Diagnostics market in the U.S. is estimated at US$42.6 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$46.8 Billion by the year 2030 trailing a CAGR of 10.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Non-Invasive Cancer Diagnostics Market – Key Trends & Drivers Summarized

Can Cancer Detection Be Revolutionized Without a Scalpel or Biopsy Needle?

Non-invasive cancer diagnostics are transforming the oncology landscape by enabling early, accurate detection and monitoring of malignancies through bodily fluids and imaging, rather than invasive tissue biopsies. Leveraging biomarkers found in blood, urine, saliva, and exhaled breath, these technologies allow clinicians to identify cancers at nascent stages, improving prognosis and reducing procedural risks. Techniques such as liquid biopsies, circulating tumor DNA (ctDNA) analysis, exosome profiling, and molecular imaging are emerging as critical tools in personalized oncology. These approaches are especially impactful in screening hard-to-access cancers like pancreatic, ovarian, and lung, where traditional biopsies pose high risk and low yield.

The convergence of genomics, proteomics, and advanced imaging has expanded the scope of non-invasive diagnostics beyond mere detection to encompass tumor typing, mutation profiling, and real-time treatment response monitoring. Liquid biopsies, for instance, are being used not only for initial cancer diagnosis but also for identifying resistance mutations during therapy and tracking minimal residual disease post-treatment. These modalities offer advantages in repeat testing, reduced patient discomfort, and faster turnaround, aligning with the growing emphasis on patient-centric and precision-based cancer care. They are increasingly being integrated into clinical guidelines and trial designs across major oncology centers worldwide.

Why Is the Demand for Less Invasive, Faster Diagnostics Gaining Ground Globally?

The demand for non-invasive diagnostics is surging due to a combination of demographic, clinical, and economic factors. Globally rising cancer incidence, aging populations, and growing awareness of the benefits of early detection are prompting health systems to adopt screening tools that are scalable, non-traumatic, and cost-effective. Governments and public health programs are prioritizing non-invasive diagnostics to expand population-based screening, especially in low- and middle-income countries where access to surgical biopsy facilities remains limited. These tools offer the possibility of early intervention before symptom onset, thereby reducing the burden of late-stage cancer treatment and improving survival rates.

In high-income countries, the shift toward value-based care models is compelling payers and providers to favor diagnostic solutions that reduce unnecessary procedures, hospitalizations, and treatment delays. Non-invasive tests enable efficient risk stratification and reduce the dependence on high-cost imaging or exploratory surgery. Furthermore, patient preference is increasingly influencing clinical choices—minimally invasive options are gaining traction among individuals wary of pain, complications, and repeated invasive monitoring. From lung cancer breath analysis to stool-DNA testing for colorectal cancer, diverse platforms are being embraced by patients seeking accessible, home-based diagnostic solutions.

How Are Cutting-Edge Technologies Elevating Diagnostic Precision and Accessibility?

Advanced technologies such as next-generation sequencing (NGS), digital PCR, microfluidics, and machine learning are enhancing the sensitivity, specificity, and scalability of non-invasive cancer diagnostics. NGS-based liquid biopsies now detect single nucleotide variants, copy number alterations, and fusion genes from as little as 1 mL of plasma, enabling comprehensive tumor profiling. Digital PCR platforms offer ultra-sensitive quantification of ctDNA, supporting longitudinal monitoring with unmatched precision. Microfluidic chips are being developed to isolate circulating tumor cells (CTCs) and exosomes in real time, supporting decentralized testing and point-of-care diagnostics.

Artificial intelligence (AI) and data analytics are being applied to radiomics and pathology imaging to extract deep phenotypic features from non-invasive scans. Radiogenomics is enabling the integration of imaging biomarkers with genomic data to non-invasively infer molecular subtypes of tumors. Cloud-connected diagnostic platforms allow clinicians to remotely monitor disease progression and therapy response using serial blood tests or imaging scans. Startups and medtech innovators are focusing on multiplexed assays, wearable sensors, and at-home diagnostic kits, democratizing access and enabling proactive cancer surveillance for high-risk populations.

What’s Driving the Breakneck Growth in the Non-Invasive Cancer Diagnostics Market?

The growth in the non-invasive cancer diagnostics market is driven by several powerful forces that are reshaping the global oncology ecosystem. A key driver is the growing adoption of precision medicine, where early, non-invasive detection is foundational to treatment planning, companion diagnostics, and real-time monitoring. Biopharma companies are increasingly collaborating with diagnostic firms to co-develop assays that guide targeted therapy selection and clinical trial enrollment, accelerating commercialization and reimbursement support.

Another crucial growth catalyst is the rising acceptance of liquid biopsies and non-invasive tests by regulatory bodies, clinical societies, and payers. The FDA’s accelerated approvals of ctDNA-based companion diagnostics and CMS’s favorable reimbursement decisions for multi-cancer detection tests have validated market potential and driven investment. Clinical trials and real-world studies continue to demonstrate the utility of these tools in detecting early-stage cancers, tracking resistance mutations, and improving treatment outcomes. In parallel, rising venture capital inflows and M&A activity are fueling innovation and global market expansion.

The expanding use of multi-omics platforms, AI-enhanced diagnostics, and decentralized sample collection is also reducing cost barriers and bringing non-invasive cancer diagnostics to outpatient settings, primary care clinics, and even patients’ homes. As oncology transitions into a continuous-care model focused on prevention, monitoring, and survivorship, non-invasive diagnostics will play a central role in transforming cancer from a late-stage crisis to a manageable chronic condition. With robust R&D pipelines, supportive policy landscapes, and strong clinical momentum, the market is poised for exponential growth across indications and geographies.

SCOPE OF STUDY:

The report analyzes the Non-Invasive Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology, Other Product Types); Cancer Type (Lung Cancer, Breast Cancer, Solid Tumors, Blood Cancer, Ovarian Cancer, Other Cancer Types); End-Use (Hospitals & Clinics, Diagnostic Centers, Ambulatory Care, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Biocept, Inc.
• Caris Life Sciences
• Datar Cancer Genetics
• DELFI Diagnostics
• Exact Sciences Corporation
• Foundation Medicine
• Freenome Holdings, Inc.
• Guardant Health, Inc.
• iCAD, Inc.
• Illumina, Inc.
• Lucence Health Inc.
• Myriad Genetics, Inc.
• Natera, Inc.
• Oncocyte Corporation
• Pacific Edge Ltd.
• QIAGEN N.V.
• Roche Diagnostics
• SAGA Diagnostics AB
• Thermo Fisher Scientific
• Veracyte, Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.